Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF-21 in morbidly obese subjects

Obesity

Volumn 21, Issue 7, 2013, Pages 1335-1342

  Haluzikova D ^a   Lacinova Z ^a   Kavalkova P ^a   Drapalova J ^a   Krizova J ^a   Bartlova M ^a   Mraz M ^a   Petr, T ^a   Vitek L ^a   Kasalicky M ^b   Haluzik M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CENTRAL MILITARY HOSPITAL   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; AMYLIN; BILE ACID; C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; INSULIN; LEPTIN; MESSENGER RNA; PANCREAS POLYPEPTIDE; PEPTIDE YY; RESISTIN;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BILE ACID BLOOD LEVEL; BIOCHEMISTRY; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; LAPAROSCOPIC SURGERY; METABOLIC PARAMETERS; MORBID OBESITY; PROTEIN BLOOD LEVEL; SLEEVE GASTRECTOMY; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

RODENTIA;

EID: 84881555231     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20208     Document Type: Article

References (38)

1. Reaven G, Abbasi F, McLaughlin T,. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res 2004; 59: 207-223.
2. Kharitonenkov A, Shanafelt AB,. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. Biodrugs 2008; 22: 37-44.
3. Prawitt J, Caron S, Staels B,. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep 2011; 11: 160-166.
4. Kharitonenkov A, Shiyanova TL, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635.
5. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143: 1741-1747.
6. Xie MH, Holcomb I, Deuel B, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999; 11: 729-735.
7. Itoh N, Ornitz DM,. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20: 563-569.
8. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 17: 1581-1591.
9. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-225.
10. Choi M, Moschetta A, Bookout AL, et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006; 12: 1253-1255.
11. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145: 2594-2603.
12. Lenicek M, Duricova D, Komarek V, et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm Bowel Dis 2011; 17: 1322-1327.
13. Lundasen T, Galman C, Angelin B, Rudling M,. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530-536.
14. Reiche M, Bachmann A, Lossner U, Bluher M, Stumvoll M, Fasshauer M,. Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters. Horm Metab Res 2010; 42: 178-181.
15. Dostalova I, Kavalkova P, Haluzikova D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008; 93: 3627-3632.
16. Schreuder TC, Marsman HA, Lenicek M, et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010; 298: G440-G445.
17. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010; 52: 1455-1464.
18. Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL,. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009; 49: 1228-1235.
19. Nishimura T, Nakatake Y, Konishi M, Itoh N,. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000; 1492: 203-206.
20. Hotta Y, Nakamura H, Konishi M, et al. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 2009; 150: 4625-4633.
21. Kharitonenkov A, Wroblewski VJ, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148: 774-781.
22. Chau MD, Gao J, Yang Q, Wu Z, Gromada J,. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci USA 2010; 107: 12553-12558.
23. Dushay J, Chui PC, Gopalakrishnan GS, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 456-463.
24. Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009; 71: 369-375.
25. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57: 1246-1253.
26. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752.
27. O'Brien PE,. Bariatric surgery: mechanisms, indications and outcomes. J Gastroenterol Hepatol 2010; 25: 1358-1365.
28. Shi X, Karmali S, Sharma AM, Birch DW,. A review of laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg 2010; 20: 1171-1177.
29. Ashrafian H, le Roux CW,. Metabolic surgery and gut hormones-a review of bariatric entero-humoral modulation. Physiol Behav 2009; 97: 620-631.
30. Setchell KDR, Lawson AM,. Bile acids. 1989. In:, Lawson AM, ed. Mass Spectrometry. Berlin and New York: Walter de Gruyter; 1989. pp 53-125.
31. Mraz M, Lacinova Z, Kavalkova P, et al. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-alpha agonist treatment. Physiol Res 2011; 60: 627-636.
32. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011; 331: 1621-1624.
33. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781-2789.
34. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr,. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
35. Mraz M, Lacinova Z, Drapalova J, et al. The effect of very-low-calorie diet on mRNA expression of inflammation-related genes in subcutaneous adipose tissue and peripheral monocytes of obese patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2011; 96: E606-E613.
36. Drucker DJ,. The role of gut hormones in glucose homeostasis. J Clin Invest 2007; 117: 24-32.
37. Santoro S, Milleo FQ, Malzoni CE, et al. Enterohormonal changes after digestive adaptation: five-year results of a surgical proposal to treat obesity and associated diseases. Obes Surg 2008; 18: 17-26.
38. Jansen PLM, van Werven J, Aarts E, et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis 2011; 29: 48-51.